/

Società

Hi

Non verificato

Hims & Hers

Di cosa scriviamo

FarmaceuticaFitnessSaluteSanitàVetrine/Shopping

56 comunicati stampa

Guarda tutti i comunicati

28/04/2026

Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

Fonte

Emittente

1.00

0

13/04/2026

Mercato azionario

Eventi

Finanza

Web e Social Network

Telefonia e Varie

Salute

Vetrine/Shopping

Fitness

Farmaceutica

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

Fonte

Emittente

1.00

0

26/03/2026

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

Fonte

Emittente

1.00

0

11/03/2026

Hims & Hers Names Kathryn Beiser as Chief Communications Officer

Fonte

Emittente

1.00

0

10/03/2026

Mercato del lavoro

Industria

Pubblico Esercizio/Vendita al dettaglio

Salute

Fitness

Accessori

Sanità

Medicina nucleare

Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

Fonte

Emittente

1.00

0

09/03/2026

Fitness

Accessori

Sanità

Farmaceutica

Vetrine/Shopping

Salute

Pubblico Esercizio/Vendita al dettaglio

Hims & Hers Announces Strategic Shift for US Weight Loss Business

Fonte

Emittente

1.00

0

23/02/2026

Web e Social Network

Telefonia e Varie

Mercato azionario

Farmaceutica

Fitness

Salute

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Fonte

Emittente

1.00

0

19/02/2026

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

Fonte

Emittente

1.00

0

05/02/2026

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

Fonte

Emittente

1.00

0

04/02/2026

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0